Who
In numbers
- Trades disclosed
- 24
- Buys
- 6
- Sells
- 0
- Bought
- $162K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 1 Jan 2022
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —20,034 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —20,034 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $12K10,000 at $1.23 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $12K10,000 at $1.23 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $22K18,000 at $1.24 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $22K18,000 at $1.24 | filing |
| 1 Jan 2026filed 2 Jan 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —25,371 at $0.00 | filing |
| 1 Jan 2026filed 2 Jan 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —33,505 at $0.00 | filing |
| 1 Jan 2026filed 2 Jan 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —33,505 at $0.00 | filing |
| 1 Jan 2026filed 2 Jan 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —25,371 at $0.00 | filing |
| 15 Jan 2025filed 17 Jan 2025 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —28,509 at $0.00 | filing |
| 15 Jan 2025filed 17 Jan 2025 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —7,100 at $0.00 | filing |
| 2 Oct 2024filed 4 Oct 2024 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —7,466 at $0.00 | filing |
| 27 Aug 2024filed 29 Aug 2024 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —18,061 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —108,333 at $0.00 | filing |
| 21 Aug 2023filed 22 Aug 2023 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $24K40,000 at $0.60 | filing |
| 2 Jan 2023filed 4 Jan 2023 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —89,041 at $0.00 | filing |
| 11 Nov 2022filed 14 Nov 2022 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $16K30,000 at $0.53 | filing |
News
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingENTX · manilatimes.net · 8 Oct 2026
0 headlines in the last 90 days name Sean Ellis; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.